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Philadelphia Chromosome-Positive Acute Lympho-
blastic Leukemia in Childhood
In pediatric patients with acute lymphoblastic leukemia (ALL), the 
Philadelphia chromosome translocation is uncommon, with a 
frequency of less than 5%. However, it is classified as a high or very 
high risk, and only 20‒30% of Philadelphia chromosome-positive (Ph+) 
children with ALL are cured with chemotherapy alone. Allogeneic 
hematopoietic stem cell transplantation from a closely matched donor 
cures 60% of patients in first complete remission. Recent data suggest 
that chemotherapy plus tyrosine kinase inhibitors (TKIs) may be the 
initial treatment of choice for Ph+ ALL in children. However, longer 
observation is required to determine whether long-term outcome 
with intensive imatinib and chemotherapy is indeed equivalent to 
that with allogeneic related or alternative donor hematopoietic stem 
cell transplantation (HSCT). Reports on the use of second-generation 
TKIs in children with Ph+ ALL are limited. A few case reports have 
indicated the feasibility and clinical benefit of using dasatinib as salvage 
therapy enabling HSCT. However, more extensive data from clinical 
trials are needed to determine whether the administration of second-
generation TKIs in children is comparable to that in adults. Because 
Ph+ ALL is rare in children, the question of whether HSCT could be a 
dispensable part of their therapy may not be answered for some time. 
An international multicenter study is needed to answer the question of 
whether imatinib plus chemotherapy could replace sibling allogeneic 
HSCT in children with Ph+ ALL.
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in adults
1). Differences in survival may be attributable in part to age-
dependent increases in unfavorable cytogenetic abnormalities. Until 
recently, Philadelphia chromosome-positive (Ph+) ALL children 
and adolescents were considered one of the poorest-risk subgroups 
of ALL patients. With chemotherapy alone, only 20–30% of 
Introduction
Age is one of the most important prognostic factors in patients with 
acute lymphoblastic leukemia (ALL). In children, long-term survival 
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children with Ph+ ALL are cured. Allogeneic hematopoietic stem 
cell transplantation (HSCT) with a closely matched donor in first 
complete remission cures 60% of patients. The Philadelphia (Ph) 
chromosome is the most common cytogenetic abnormality in 
adult ALL, comprising 20‒30% of adult cases; however, it occurs 
in only 3‒5% of pediatric cases
2). The Ph chromosome results from 
a reciprocal translocation between chromosomes 9 and 22 (t[9,22]
[q34;q11]), which produces a fusion gene on chromosome 22, namely, 
the breakpoint cluster region-Abelson leukemia viral proto-oncogene 
(BCR-ABL). BCR-ABL fusion proteins are constitutively active 
tyrosine kinases that can alter multiple signaling pathways, which 
contribute to tumor growth and proliferation. The molecular weight 
of this protein depends on the precise chromosome breakpoint. 
Most patients with ALL express a 190-kDa protein (p190), whereas 
the others express a 210-kDa oncoprotein (p210), which is also 
commonly found in chronic myeloid leukemia (CML)
3).  
The role of allogeneic hematopoietic stem cell 
transplantation as a first-line therapy for Ph+ ALL 
Although complete remissions (CRs) may occur in 70‒90% of 
patients with Ph+ ALL who receive intensive chemotherapy alone, 
most patients relapse and die within 12 months of treatment
4). 
Allogeneic HSCT substantially improves long-term survival rates, 
and in a large-scale trial, the 5-year relapse-free survival rate in the pre-
imatinib era was 57% in patients who underwent a sibling allogeneic 
HSCT, 66% in patients who underwent a matched unrelated 
donor allogeneic HSCT, and 44% in patients who underwent an 
autologous HSCT, but the survival rate in patients who received 
chemotherapy alone was 10%. Although the allogeneic HSCT group 
fared worse initially because of high rates of transplantation-related 
mortality, the lower relapse risk translated to a higher 5-year event-
free survival rate (EFS) (41% for sibling donor and 36% for matched 
unrelated donor) and a higher 5-year overall survival rate (OS) (44% 
for sibling donor and 36% for matched unrelated donor) compared 
with chemotherapy alone (EFS, 9%; OS, 10%) and autologous 
HSCT (EFS and OS, 29%)
5). Several factors influence the outcome 
of patients who undergo allogeneic HSCT. Patients who underwent 
allogeneic HSCT in first CR had substantially better outcomes than 
those who underwent allogeneic HSCT during second or later CR. 
Other favorable factors include younger age, total body irradiation 
conditioning, the use of a human leukocyte antigen-identical sibling 
donor, and the occurrence of acute graft-versus-host disease.
Recently, an Italian group analyzed treatment results according 
to time period. In a previous analysis of 326 children with Ph+ ALL 
treated between 1986 and 1996, compared with chemotherapy alone, 
HSCT with matched related donors yielded a superior outcome; 
however, this advantage did not extend to HSCT with matched 
unrelated donors
6). To evaluate the impact of recent improvements in 
chemotherapy and transplantation, a similar analysis was performed 
on patients treated in the following decade
7). In this study, the 
advantage of transplantation on disease-free survival (DFS) appeared 
during the second year of follow up and became significantly more 
evident with each successive year, which suggests greater protection 
against late relapse with HSCT (P<0.001). According to the Cox 
model, the hazard of failure (relapse or death in remission) at 5 years 
was reduced by two-thirds by HSCT than with chemotherapy 
alone (hazard ratio [HR], 0.32; 95% CI, 0.20‒0.52). According to 
univariate comparison of the DFS curves at the 5-year time point, the 
advantage of transplantation was borderline significant (P=0.049). 
However, although the improvements in outcome achieved during 
the time period from 1996 to 2005 were statistically significant, only 
a small (10%) effect was observed on OS. Treatment with either 
chemotherapy or HSCT during this time period without tyrosine 
kinase inhibitor (at least during the front-line treatment program) 
resulted in long-term survival rates of less than 50% for all groups 
analyzed. Overall, only 45% of children with Ph+ ALL were alive 7 
years after diagnosis, a result that remains unacceptable, and further 
optimization of the chemotherapy or HSCT regimen is unlikely to 
lead to major improvements in outcome
7).
Imatinib, a major advance in the treatment of 
Ph+ ALL
Imatinib mesylate, the first BCR-ABL inhibitor to gain clinical 
Table 1. Key Points about Ph+ ALL in Children
Uncommon among pediatric ALL patients, with a frequency of less than 5%
The most common cytogenetic abnormalities in adult ALL, comprising 20 to 
30% of adults
Classified as high or very high risk
With chemotherapy alone, only 20‒30% of children with Ph+ ALL are cured. 
Allogeneic hematopoietic stem cell transplantation in first complete remission 
cures 60% of patients with a closely matched donor. 
Recent data suggests that chemotherapy plus TKIs may be the initial 
treatment of choice for Ph+ ALL in children.
Second-generation TKIs are more potent inhibitors of the BCR-ABL kinase 
when compared with imatinib. Only dasatinib and nilotinib are currently 
being evaluated as therapies for Ph+ ALL.
Side effects of TKI including gastric upset, cytopenias, peripheral edema,   
liver toxicity, pleural effusion, growth retardation, and possible premature 
closure of the growth plates resulting in short stature.
When TKI is added to therapy, higher complete remission rate without 
additional toxicity allows more patients to undergo allogeneic HSCT 
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approval, partially blocks the adenosine triphosphate (ATP) binding 
site of BCR-ABL, thus preventing the conformational switch of the 
oncogenic protein to the activated form
8). Early trials of imatinib were 
performed in adults with Ph+ ALL or CML in lymphoid or myeloid 
blast crisis. Imatinib doses ranged from 300 to 600 mg/day, and 73% 
of evaluable patients had a 50% or greater reduction in marrow or 
peripheral blasts after 4 weeks of therapy. Toxicity was minimal, but 
a possible effect on platelet function leading to an increased bleeding 
tendency was identified
9).
Data for children lagged behind that for adults. In a Children’s 
Oncology Group (COG) Phase I trial, imatinib was increased from 
260 to 570 mg/m
2/day in 31 children. Toxicities were minimal, 
occurring in less than 5% of courses, and were primarily grade 1 
or 2 nausea, vomiting, fatigue, diarrhea, and reversible increases in 
serum transaminases. No maximum tolerated dosage was defined. 
Doses of 260 and 340 mg/m
2 provided systemic exposures similar 
to those of adults who were treated with daily doses of 400 and 600 
mg, respectively
10). On the basis of these findings, Phase II/III trials 
were developed to evaluate the role of chemotherapy plus imatinib in 
childhood Ph+ ALL. The 3-year EFS was 88±11% for chemotherapy 
plus imatinib, which is more than twice that of historical controls 
(35±4%; P<0.0001). The results were comparable to those of pa-
tients biologically assigned to treatment with human leukocyte 
antigen (HLA)-identical sibling stem cell transplantation (SCT) 
(57±22%) and those of patients treated with unrelated donor SCT 
(71.6±19.0%)
11). This suggests that chemotherapy plus tyrosine kinase 
inhibitors (TKIs) may be the initial treatment of choice for Ph+ ALL 
in children. However, the numbers in this trial are small and the 
historical controls included children treated over a long period in 
the past. Furthermore, the comparative survival curves highlighted 
the very short follow up for the study cohort. This is particularly 
relevant since earlier studies examining the outcome of Ph+ ALL 
demonstrated the occurrence of late relapses in children treated with 
chemotherapy alone, whereas relapses following allogeneic HSCT 
typically occurred early or were absent. In summary, the cumulative 
evidence indicates that imatinib is an extremely valuable addition 
to induction therapy for Ph+ ALL. Imatinib certainly increases the 
ability of therapy to generate complete remissions and very likely 
allows more patients to undergo allogeneic HSCT. However, it 
appears unlikely to represent a long-term curative option for patients 
with Ph+ ALL. The standard practice continues to be imatinib 
used in combination with chemotherapy from diagnosis in order to 
achieve a rapid response and facilitate early allogeneic HSCT, which 
is presently considered to offer the best anti-leukemic activity
12).
Second-generation TKIs
Several second-generation TKIs have been identified as potential 
therapies for Ph+ ALL. These include dasatinib, nilotinib, bosutinib, 
DCC-2036, AP24534, and AT9283
13). All of these agents are more 
potent inhibitors of BCR-ABL kinase than imatinib, but only 
nilotinib and dasatinib are currently being evaluated as therapies for 
Ph+ ALL.
1. Dasatinib
Dasatinib, a dual SRC and ABL inhibitor, has 325-fold greater 
potency than imatinib in cells transduced with unmutated BCR-ABL 
and is active against many BCR-ABL mutations that confer imatinib 
resistance
14). Although it is more toxic than imatinib, dasatinib is a 
more attractive Ph+ ALL therapy candidate than imatinib because of 
its broader spectrum of action. Furthermore, dasatinib has marked 
activity in relapsed or resistant Ph+ ALL, and another advantage 
of dasatinib is that, unlike imatinib, it has excellent central nervous 
sys  tem (CNS) penetration. In one report, dasatinib produced im-
provement in the cerebrospinal fluid in all 11 adult and pediatric 
patients with CNS Ph+ ALL, and the response was long-lasting in 7 
patients
15). Myelosuppression was common but not dose limiting, and 
tolerability in the context of combination chemotherapy was less clear. 
Dasatinib has been approved for use by the USA and Korea FDA for 
patients with Ph+ ALL who have failed to respond to imatinib, and 
clinical trials evaluating its efficacy in patients with newly diagnosed 
Ph+ ALL are ongoing. Currently, the COG is evaluating dasatinib 
in combination with the same intensive chemotherapy backbone 
as in the previous study with imatinib. The primary goals of this 
study are to assess the safety and feasibility of substituting dasatinib 
for imatinib in the previous COG chemotherapy backbone and to 
determine whether intensive chemotherapy plus dasatinib will result 
in a 3-year EFS of at least 60% in patients with Ph+ ALL
16). Given 
the early superiority of dasatinib in CML, if dasatinib is well tolerated 
in the COG trial, a randomized comparison versus imatinib in Ph+ 
ALL will be considered.
2. Nilotinib
Nilotinib is a highly specific BCR-ABL inhibitor that is ap-
proximately 30-fold more potent than imatinib, and is active in vitro 
against 32 of 33 BCR-ABL mutants
17). A phase I study of nilotinib in 
patients with imatinib-resistant CML and Ph+ ALL indicated that 
nilotinib had a relatively favorable safety profile, and responses were 
noted in a subset of adult patients with imatinib-resistant Ph+ ALL. 
In particular, 10% of patients who had hematologic relapses achieved 
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molecular signs of ALL achieved complete molecular remission after 
nilotinib therapy
18). A subsequent phase II study of nilotinib (400 
mg twice daily) in relapsed or refractory Ph+ ALL reported that 24% 
patients attained a complete hematologic response
19). 
Side effects of TKI with chemotherapy
Imatinib has numerous short-term side effects including gastric 
upset, cytopenia, peripheral edema, and liver toxicity (reversible 
elevation of transaminases). Pleural effusion, which was not severe, 
has also been observed with dasatinib. The only major toxicity 
observed with imatinib in prepubertal children has been growth 
retardation and possible premature closure of the growth plates 
resulting in short stature
20, 21). This has been observed with long-term 
imatinib usage in children with CML and may not be a major factor 
when used for only approximately 2.5 years as in the COG study. 
Other TKIs probably have the same effect on growth .
The impact of known risk factors in childhood ALL 
Age, white blood count (WBC) at diagnosis, minimal residual 
disease (MRD), and complex cytogenetics are the well-known risk 
factors that affect outcome in children with ALL. In a retrospective 
analysis of patients treated without TKI, a high WBC count and 
age over 10 years suggested a poor prognosis with chemotherapy. 
However, in the recent COG trial, the differences were much lower 
and were not significantly different
11). A slow prednisone response 
and higher MRD also suggested a poor prognosis in German trials 
and are being used for risk assignment in the current trial
22). In 
the COG trial with longer follow up, MRD appears to be more 
prognostic, but is still not significant. Therefore, MRD is currently 
being used to determine high-risk patients in the COG dasatinib plus 
chemotherapy trial. Complex cytogenetics has also been shown to be 
a poor prognostic factor in adult Ph+ ALL
23). However, in the COG 
trial, complex cytogenetics did not predict outcome
24).
Conclusion and future directions
Ph+ ALL children and adolescents were once the poorest-risk 
subgroups of ALL patients. With chemotherapy alone, only 20‒30% 
of children with Ph+ ALL are cured. Allogeneic HSCT from a 
closely matched donor in first complete remission cures 60% of 
patients. Although TKIs have limited activity against Ph+ ALL 
as a single agent, they have been evaluated in combination with 
chemotherapy and have shown promise. Early results of the COG 
trial have shown an 88% 3-year EFS for Ph+ patients treated with 
intensive chemotherapy plus continuous imatinib. This suggests 
that chemotherapy plus TKIs may be the initial treatment of choice 
for children with Ph+ ALL. However, in this trial, the numbers are 
small and confirmatory results are not yet available. It is possible that 
the major benefit of using TKI will be accompanying transplant; 
first, to allow a greater proportion of patients to receive allogeneic 
HSCT, and second, to provide a sufficient level of post-transplant 
disease suppression to allow time for a graft-versus-leukemia effect to 
eliminate residual ALL in those who undergo transplantation with 
persistent MRD that is not eradicated by the conditioning therapy. 
The first patient group in whom omission of transplant is likely to 
be tested will be in children, because in younger patients there is a 
better outcome with chemotherapy alone, and younger individuals 
have more to lose by risking the long-term adverse consequences of 
allogeneic HSCT. However, because Ph+ ALL is rare in children, 
the question of whether HSCT can be a dispensable part of their 
therapy may not be answered for some time. An international 
multicenter study is needed to answer the question of whether 
imatinib plus chemotherapy could replace sibling allogeneic HSCT 
in children with Ph+ ALL.  Key points about Ph+ ALL in children 
are summarized in Table 1.
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